entimICER DARE dramatically improves how pharmaceutical companies can manage, analyze, and report on clinical data.
Paris – 06/03/2006 – entimo AG, a leading company providing manufacturers of the pharmaceutical and crop science industries with high quality e-business Research & Development (eR&D) products and solutions, as well as custom IT solutions for the regulatory authorities, today announced the general availability of its flagship product entimICE DARE to all customers worldwide.
entimICE DARE is a comprehensive and flexible product that ensures seamless operation across different stages of clinical development by enabling the user to view, manage, analyze and report data across clinical applications, and across projects or trials, within the same environment, and in a regulatory compliant manner. entimICE DARE is designed to meet the needs of clinical research and development personnel - such as clinical monitors, clinical research associates, biostatisticians, programmers, etc. - involved in the integration, management, analysis and reporting of clinical trial data. Now pharmaceutical companies can have a customizable repository based data analysis and reporting environment that is cost effective, easy to implement, and tailored to their business - all without having to write a single line of code.
"entimICE DARE is filling the gap of traceability between CDMS and submission in a customizable manner" said Juergen Spieler, chief executive officer of entimo AG. "With this release, entimo AG raises the bar for clinical data repository based solutions for managing, analyzing and reporting of clinical data, delivering pharmaceutical companies unprecedented value. The enhanced functionality that our entimICE DARE solution provides enables pharmaceutical companies of all sizes to meet the increasing demands of regulatory compliance, such as GxP and CFR Part 11, head-on, while providing them the flexibility to customize their solution based on their unique business requirements."
entimICE DARE provides:
General features
Regulatory compliance
Secure access
Structure definition
Traceability
Workflow
Data management
Statistical analysis and program management and execution
For more information, please visit the company's website at www.entimo.com.
Moderna’s mRNA-1010 Flu Vaccine Meets Efficacy Goals in Phase III Trial of Adults 50+
July 10th 2025In the P304 Phase III study, Moderna’s mRNA-1010 demonstrated a 26.6% relative efficacy over a standard-dose flu vaccine in adults aged 50+, showing consistent protection across strains and age groups.
Unifying Industry to Better Understand GCP Guidance
May 7th 2025In this episode of the Applied Clinical Trials Podcast, David Nickerson, head of clinical quality management at EMD Serono; and Arlene Lee, director of product management, data quality & risk management solutions at Medidata, discuss the newest ICH E6(R3) GCP guidelines as well as how TransCelerate and ACRO have partnered to help stakeholders better acclimate to these guidelines.
QWINT-1 Trial: Once-Weekly Efsitora Matches Daily Glargine in Type 2 Diabetes Management
July 10th 2025Results from the Phase III QWINT-1 trial show that Eli Lilly’s once-weekly insulin efsitora is noninferior to once-daily glargine in reducing HbA1c among insulin-naïve adults with type 2 diabetes, offering a simplified fixed-dose regimen with fewer hypoglycemic events and less treatment burden.